Pilotto Andrea, Padovani Alessandro, Borroni Barbara
Clinica Neurologica, Università degli Studi di Brescia, Pza Spedali Civili, 1-25100 Brescia, Italy.
Biomed Res Int. 2013;2013:689591. doi: 10.1155/2013/689591. Epub 2013 Nov 27.
The discovery of monogenic forms of Alzheimer's Disease (AD) associated with mutations within PSEN1, PSEN2, and APP genes is giving a big contribution in the understanding of the underpinning mechanisms of this complex disorder. Compared with sporadic form, the phenotype associated with monogenic cases is somewhat broader including behavioural disturbances, epilepsy, myoclonus, and focal presentations. Structural and functional imaging show typical early changes also in presymptomatic monogenic carriers. Amyloid imaging and CSF tau/A β ratio may be useful in the differential diagnosis with other neurodegenerative dementias, especially, in early onset cases. However, to date any specific biomarkers of different monogenic cases have been identified. Thus, in clinical practice, the early identification is often difficult, but the copresence of different elements could help in recognition. This review will focus on the clinical and instrumental markers useful for the very early identification of AD monogenic cases, pivotal in the development, and evaluation of disease-modifying therapy.
早发性阿尔茨海默病(AD)的单基因形式与PSEN1、PSEN2和APP基因的突变有关,这一发现为理解这种复杂疾病的潜在机制做出了巨大贡献。与散发性形式相比,单基因病例相关的表型更为广泛,包括行为障碍、癫痫、肌阵挛和局灶性表现。结构和功能成像显示,症状前单基因携带者也有典型的早期变化。淀粉样蛋白成像和脑脊液tau/Aβ比值可能有助于与其他神经退行性痴呆进行鉴别诊断,尤其是在早发病例中。然而,迄今为止,尚未发现不同单基因病例的任何特异性生物标志物。因此,在临床实践中,早期识别往往很困难,但不同因素的共同存在可能有助于识别。本综述将重点关注对AD单基因病例进行极早期识别有用的临床和影像学标志物,这对疾病修饰治疗的开发和评估至关重要。